Maryland is currently home to 2668 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
NCT06034002
Recruiting
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Myeloproliferative Neoplasms
Register for Updates
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
NCT05468489
Recruiting
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Sandra and Malcolm Berman Cancer Institute at Greater Baltimore Medical Center, Baltimore, Maryland
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
NCT05465174
Recruiting
The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
05/22/2025
Locations: John Hopkins University, Baltimore, Maryland
Conditions: Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
Register for Updates
SPIROMICS Study of Early COPD Progression (SOURCE)
NCT05033990
Recruiting
This is an observational study of 1000 participants to further define the nature of early chronic obstructive pulmonary disease (COPD) in younger, at-risk individuals. The study has three main goals: * To use CT scan imaging to identify which smokers will develop COPD. * To identify biomarkers predictive of smokers that will develop COPD. * To determine if sputum (phlegm) can be analyzed to predict which smokers will develop COPD. Procedures (methods): All participants will undergo study rela... Read More
Gender:
ALL
Ages:
Between 30 years and 55 years
Trial Updated:
05/22/2025
Locations: Johns Hopkins Bayview Medical Center, Baltimore, Maryland
Conditions: COPD, Early-Onset
Register for Updates
The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)
NCT04866810
Recruiting
Background: The gut microbiome is made up microorganisms. These include the good and bad bacteria that live in the digestive tract. Changes in the gut microbiome have been linked to the development of cancer. Researchers want to learn more about the effects of modulating the microbiome with diet and exercise. Objective: To see if nutritional intake and physical activity change the gut microbiome in people with melanoma. Eligibility: Adults age 18 and older with previously untreated melanoma... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Melanoma
Register for Updates
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
NCT01790152
Recruiting
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.
Gender:
ALL
Ages:
All
Trial Updated:
05/22/2025
Locations: Sinai Hospital of Baltimore, Baltimore, Maryland
Conditions: Hodgkin Lymphoma in Remission, Leukemia in Remission, Lymphoblastic Lymphoma, Osteosarcoma, Recurrent Leukemia, Recurrent Lymphoma, Recurrent Malignant Neoplasm
Register for Updates
First-in-Human Single and Multiple Dose of HL-400
NCT06997484
Recruiting
This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics of HL-400 (a NLRP3 inhibitor) following oral single and multiple ascending dose administration.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/21/2025
Locations: Pharmaron CPC, Inc., Baltimore, Maryland
Conditions: Parkinson Disease
Register for Updates
INJECTABLE COLD ENERGY THERAPY FOR THE MANAGEMENT OF CHRONIC PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE
NCT06700109
Recruiting
The goal of this clinical trial is to evaluate the effectiveness of Neural Ice for pain management associated with knee osteoarthritis in adults aged 22-80 years. Participants will attend study visits and complete subject diaries. Participants will be followed for 6 months after study procedure.
Gender:
ALL
Ages:
Between 22 years and 80 years
Trial Updated:
05/21/2025
Locations: NextStage Clinical Research Regenerative Orthopedics and Sports Medicine, North Bethesda, Maryland
Conditions: Osteoarthritis (OA) of the Knee
Register for Updates
Community Engagement Alliance Against Disparities
NCT06607341
Recruiting
The Community Engagement Alliance against Disparities - Washington District of Columbia, Maryland, Virginia (CEAL DMV), is a multi-community and multi-university consortium. Through collaboration and shared leadership, the CEAL-DMV the consortium- comprising five institutions: George Washington University, Howard University, Johns Hopkins University, Morgan State University, and the University of Maryland, Baltimore-has established a regional structure for bi-directional community involvement to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Johns Hopkins University School of Nursing, Baltimore, Maryland
Conditions: Diabetes, Pre-diabetes, Hypertension, Overweight and Obesity
Register for Updates
Sequential Multiple Assignment Randomized Trial for Bipolar Depression
NCT06433635
Recruiting
This is a sequential multiple assignment randomized trial for adults (ages \> 18) with a bipolar disorder type 1 diagnosis currently experiencing a depressive episode. It is a randomized pragmatic trial that will compare four commonly prescribed treatments for bipolar depression, which includes three FDA-approved medications (Cariprazine, Quetiapine and Lurasidone) and one antipsychotic/antidepressant combination (Aripiprazole/Escitalopram).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/21/2025
Locations: John Hopkins, Baltimore, Maryland
Conditions: Bipolar I Disorder, Depression
Register for Updates
Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer
NCT05996523
Recruiting
Background: Cancers in and around the mouth associated with human papilloma virus (HPV) are common. Two treatments (the drug pembrolizumab and the HPV vaccine PRGN-2009) have been shown to work well when used individually against these cancers. Researchers want to find out if they might work better when used together. Objective: To test pembrolizumab combined with PRGN-2009 in people with HPV-positive cancers in and around the mouth. Eligibility: Adults aged 18 and older newly diagnosed wit... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/21/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Oropharyngeal Squamous Cell Carcinoma (SCC)
Register for Updates
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
NCT05849480
Recruiting
Background: Biliary tract carcinoma (BTC) is cancer of the slender tubes that carry fluids in the liver. People with advanced BTC have few treatment options, and their survival rates are very low. Objective: To test a study drug (CDX-1140) combined 3 other drugs (capecitabine, oxaliplatin, Keytruda) in people with BTC. Eligibility: Adults aged 18 years or older with BTC that progressed after treatment and is not eligible for surgery or liver transplant. Design: Participants will be screen... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/21/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct
Register for Updates